DexCom Inc $ 156.92 0.25 (0.16%)
On watch
Volume:
653,153
Avg Vol (1m):
809,116
Market Cap $:
14.31 Bil
Enterprise Value $:
14.03 Bil
P/E (TTM):
0.00
P/B:
20.52
| Earnings Power Value | ||
| Net Current Asset Value | ||
| Tangible Book | ||
| Projected FCF | ||
| Median P/S Value | ||
| DCF (FCF Based) | ||
| DCF (Earnings Based) | ||
|
Price: $156.92 | ||
Manual of Stocks™ Web
Financial Strength | 5/10 |
| Current | Vs Industry | Vs History | |
|---|---|---|---|
| Cash-To-Debt | 1.25 | ||
| Equity-to-Asset | 0.33 | ||
| Debt-to-Equity | 1.6 | ||
| Debt-to-EBITDA | -12.64 | ||
| Piotroski F-Score | 4 | ||
| Altman Z-Score | 6.9 | ||
| Beneish M-Score | -2.97 | ||
| WACC vs ROIC | |||
Profitability | 4/10 |
| Current | Vs Industry | Vs History | |
|---|---|---|---|
| Operating Margin % | -13.58 | ||
| Net Margin % | -13.96 | ||
| ROE % | -27.82 | ||
| ROA % | -10.55 | ||
| ROC (Joel Greenblatt) % | -43.04 | ||
| 3-Year Revenue Growth Rate | 32.4 | ||
| 3-Year EBITDA Growth Rate | -13.5 | ||
| 3-Year EPS without NRI Growth Rate | -26 |
Ratios |
| Current | Vs Industry | Vs History | |
|---|---|---|---|
| Forward PE Ratio | 121.95 | ||
| PB Ratio | 20.52 | ||
| PS Ratio | 11.57 | ||
| Price-to-Free-Cash-Flow | 362.4 | ||
| Price-to-Operating-Cash-Flow | 84.91 | ||
| EV-to-EBIT | -112.26 | ||
| EV-to-EBITDA | -161.1 | ||
| EV-to-Revenue | 11.49 | ||
| Current Ratio | 6.05 | ||
| Quick Ratio | 5.64 | ||
| Days Inventory | 62.76 | ||
| Days Sales Outstanding | 64.93 | ||
| Days Payable | 77.91 |
Dividend & Buy Back |
| Current | Vs Industry | Vs History | |
|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -3.3 |
Valuation & Return |
| Current | Vs Industry | Vs History | |
|---|---|---|---|
| Price-to-Tangible-Book | 21.09 | ||
| Price-to-Intrinsic-Value-Projected-FCF | 18.05 | ||
| Price-to-Median-PS-Value | 0.93 | ||
| Earnings Yield (Greenblatt) % | -0.89 |